BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foglia E, Bonfanti P, Rizzardini G, Bonizzoni E, Restelli U, Ricci E, Porazzi E, Scolari F, Croce D. Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world. PLoS One 2013;8:e57777. [PMID: 23460905 DOI: 10.1371/journal.pone.0057777] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Lu ZK, Xiong X, Lee T, Wu J, Yuan J, Jiang B. Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis. Front Pharmacol 2021;12:700012. [PMID: 34737696 DOI: 10.3389/fphar.2021.700012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Marcellusi A, Bini C, Andreoni M, Antinori A, Mennini FS. Valutazione delle conseguenze epidemiologiche ed economiche generate dal ritardo di trattamento dei pazienti HIV-positivi causato dalla pandemia COVID-19. Glob Reg Health Technol Assess 2021;8:147-54. [PMID: 36627876 DOI: 10.33393/grhta.2021.2279] [Reference Citation Analysis]
3 Azar FEF, Aboutorabi A, Afrouzi M, Hajahmadi M, Karpasand S. Long-term outcomes after revascularization and medical therapy in premature coronary artery disease for cost-effectiveness study: A systematic review protocol. J Educ Health Promot 2021;10:314. [PMID: 34667814 DOI: 10.4103/jehp.jehp_1590_20] [Reference Citation Analysis]
4 Boyer S, Nishimwe ML, Sagaon-Teyssier L, March L, Koulla-Shiro S, Bousmah MQ, Toby R, Mpoudi-Etame MP, Ngom Gueye NF, Sawadogo A, Kouanfack C, Ciaffi L, Spire B, Delaporte E; 2-Lady Group. Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa. Pharmacoecon Open 2020;4:45-60. [PMID: 31273686 DOI: 10.1007/s41669-019-0157-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Matza LS, Chung KC, Kim KJ, Paulus TM, Davies EW, Stewart KD, McComsey GA, Fordyce MW. Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation. Qual Life Res 2017;26:1785-98. [PMID: 28341926 DOI: 10.1007/s11136-017-1519-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
6 Marcellusi A, Viti R, Russo S, Andreoni M, Antinori A, Mennini FS. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective. Clin Drug Investig 2016;36:377-87. [PMID: 26940802 DOI: 10.1007/s40261-016-0382-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Sanni-oba MB, Uthman OA, Nachega JB. Cost-effectiveness of once-daily versus twice-daily regimens in the treatment of HIV infection in sub-Saharan Africa: a probabilistic decision model. F1000Res 2016;5:2681. [DOI: 10.12688/f1000research.9954.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Garattini L, Curto A, Padula A, Freemantle N. Real-world evidence in economic evaluations: Really realistic? J R Soc Med 2016;109:404-7. [DOI: 10.1177/0141076816671258] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ruggeri M, Manca A, Coretti S, Codella P, Iacopino V, Romano F, Mascia D, Orlando V, Cicchetti A. Investigating the Generalizability of Economic Evaluations Conducted in Italy: A Critical Review. Value Health 2015;18:709-20. [PMID: 26297100 DOI: 10.1016/j.jval.2015.03.1795] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
10 Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration. Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. Clin Infect Dis 2015;60:1262-8. [PMID: 25567330 DOI: 10.1093/cid/ciu1167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
11 Codella P, Coretti S, Fiore A, Rizzardini G, Ruggeri M. Cost-Effectiveness Studies in HIV Treatment with Lopinavir/Ritonavir: A Review. Global & Regional Health Technology Assessment 2014;1:GRHTA.5000184. [DOI: 10.5301/grhta.5000184] [Reference Citation Analysis]
12 Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Ther Clin Risk Manag 2014;10:9-15. [PMID: 24379676 DOI: 10.2147/TCRM.S49428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]